

Appendices

LEGISLATIVE CHRONOLOGY

NOV. 1, 1948

The National Microbiological Institute was established under authority of section 202 of the Public Health Service Act, as implemented by General Circular No. 55, Organization Order No. 20, dated October 8, 1948.

DEC. 29, 1955

NIAID was established (replacing the National Microbiological Institute) under authority of the Omnibus Medical Research Act (Public Law 81-692, 64 Stat. L. 443), as implemented by a Public Health Service Briefing Memorandum of November 4, 1955, from the Surgeon General to the Secretary of Health, Education, and Welfare.

NOV. 4, 1988

NIAID was provided with additional authorities for AIDS research under Title II of the Health Omnibus Programs Extension of 1988 (HOPE legislation) (Public Law 100-607), the first major law to address AIDS research, information, education, and prevention.

AUG. 14, 1991

The Public Health Service Act was amended by Public Law 102-96, the Terry Beirn Community-Based AIDS Research Initiative Act of 1991, which reauthorized NIAID's Community Programs for Clinical Research on AIDS (CPCRA). CPCRA was renamed in honor of Mr. Beirn (an AIDS activist and congressional staffer who died in 1991) and was reauthorized for an additional 5 years.

JUNE 10, 1993

The Public Health Service Act was amended by Public Law 103-43, the National Institutes of Health Revitalization Act of 1993. This comprehensive legislation required NIAID to include research on tropical diseases in its mission statement and directs the Secretary, U.S. Department of Health and Human Services, to ensure that individuals with expertise in chronic fatigue syndrome or neuromuscular diseases are appointed to appropriate NIH advisory committees.

DEC. 14, 1993

The Preventive Health Amendments of 1993 were passed, which included provisions requiring the Director, NIAID, to conduct or support research and research training regarding the cause, early detection, prevention, and treatment of tuberculosis. (The Institute already had authority to conduct such research under its authorities in Title IV, Public Health Service Act.)

NOV. 29, 1999

The fiscal year 2000 Appropriations Act (Public Law 106-113) established the NIH Challenge Grants program to promote joint ventures between the NIH and the biotechnology, pharmaceutical, and medical device industries. A one-time funding level of \$20 million was provided within the Public Health and Social Services Emergency Fund.

OCT. 17, 2000

The Children’s Health Act (Public Law 106-310) required the Directors of NIAID and the National Institute of Arthritis and Musculoskeletal and Skin Diseases to expand and intensify the activities of their Institutes with respect to research and related activities concerning juvenile arthritis and related conditions.

NOV. 13, 2000

The Public Health Improvement Act (Public Law 106-505) authorized the NIAID Director to establish a program of clinical research and training awards for sexually transmitted infections.

Previous Directors

- Victor H. Haas, M.D., 1948–1957
- Justin M. Andrews, Sc.D., 1957–1964
- Dorland J. Davis, M.D., D.P.H., 1964–1975
- Richard M. Krause, M.D., 1975–1984

TECHNOLOGY TRANSFER

Technology transfer in Federal laboratories facilitates the dissemination of new technologies and research materials developed by Government scientists. This technology transfer fuels further innovation and commercialization by the extramural research and development community, ultimately resulting in an improvement in the public health and an increase in the competitiveness of U.S. industry. Federal legislation mandates and defines the Government's technology transfer activities. The key pieces of legislation are the Federal Technology Transfer Act of 1986 and the National Technology Transfer and Advancement Act of 1995.

The NIAID Office of Technology Development (OTD) accomplishes technology transfer by facilitating the transfer of significant research advances and resources to the broader scientific community and the development of collaborative relationships between NIAID scientists, industry, and academia. NIAID uses various mechanisms to accomplish these ends, including Material Transfer Agreements (MTAs), Cooperative Research and Development Agreements (CRADAs), Materials-CRADAs (M-CRADAs), Confidential Disclosure Agreements (CDAs), Clinical Trial Agreements (CTAs), Drug Screening Agreements (DSAs), and, through the NIH Office of Technology Transfer (OTT), the patenting of inventions and the negotiation of various license agreements.

NIAID scientists report inventions to OTD by submitting Employee Invention Reports (EIRs). The EIRs are reviewed by OTD and, with the

assistance of the NIAID Technology Evaluation Advisory Committee (TEAC), are evaluated for the purpose of filing domestic and foreign patent applications. In fiscal year (FY) 2003, TEAC reviewed 27 intramural EIRs and recommended that a patent application be filed on 22 of them. NIAID currently has 342 active U.S. patent properties, including 168 issued patents and 174 pending patent applications.

NIAID had a total of 245 active license agreements in FY 2003 for both patented inventions and biological materials. These licenses generated about \$10.3 million in royalty income, which was first used to pay NIAID inventors their share according to Federal law and NIH policy. The Institute also distributed royalty income to intramural laboratories to support research projects and equipment acquisition that otherwise would not have been accomplished with appropriated funds. The remaining royalties were used to pay OTD's entire operating budget, including patent prosecution fees, OTD staff salaries, associated office expenses, and overhead charged by OTT.

In FY 2003, a total of 192 MTAs, 12 CTAs, 59 CDAs, 5 CRADAs, 14 M-CRADAs, and 21 other agreements, not including the screening agreement related to severe acute respiratory syndrome (SARS) discussed below, were executed and negotiated by OTD. NIAID extramural divisions referred technology transfer issues to OTD on 5 contracts, and OTD NIAID scientists performed research under 33 CRADAs and 40 M-CRADAs in FY 2003. The following table provides a history of NIAID's patent, license, and CRADA activities.

NIAID Technology Transfer Activities

Fiscal Year	Pending Patents	Issued Patents	Licenses in Effect	Active CRADAs
1994	85	65	84	29
1995	96	71	101	31
1996	95	84	120	42
1997	128	91	131	71
1998	154	83	155	95
1999	169	94	195	74
2000	229	100	196	86
2001	194	125	190	93
2002	147	139	197	85
2003	174	168	245	71

Technology Transfer Highlights

OTD supported NIAID's response to SARS by drafting an agreement for use in a collaboration between the NIAID Division of Microbiology and Infectious Diseases (DMID) and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to provide resources to screen possible anti-SARS proprietary compounds. This screening agreement has been provided to 190 companies, of which more than 40 requested that the screening agreement be renegotiated by OTD. In addition to this screening agreement, OTD negotiated and completed at least 13 other SARS-related agreements.

In FY 2003, OTD negotiated or facilitated the following public-private partnerships.

Evaluation of Adenoviral Encoding Proteins Associated With SARS (GenVec)

Recombinant adenoviral vectors have been widely investigated in recent years as a gene delivery system for gene therapy and vaccination. Recombinant adenoviral vectors offer a promising strategy for development of a candidate SARS vaccine that could be effective

in humans. Investigators at the Vaccine Research Center (VRC), NIAID, the NIH, and GenVec, Inc. (GenVec) will collaborate to evaluate and develop adenoviral vectors expressing modified SARS genes. The collaboration will evaluate adenovectors for potential application, such as a SARS preventive vaccine. VRC will provide GenVec with several modified SARS genes, and GenVec will construct and produce recombinant adenovectors that express SARS genes, using the GenVec adenovector and cell line system. The overall goal is to provide VRC with advanced vector technologies suitable for rapid advancement toward clinical trial.

Analysis of the Immune Response to Hepatitis C Virus (Innogenetics)

Under this CRADA, investigators in the Hepatitis Viruses Section, Laboratory of Infectious Diseases, Division of Intramural Research at NIAID, and Innogenetics will perform basic and applied studies of the immune response to hepatitis C virus (HCV) in nonhuman primates in order to determine how to modify the host response to HCV for therapeutic and immunoprophylactic benefit.

Use of Quantum Dots for Improved Cellular Classification in Flow Cytometry (Quantum Dot Corporation)

Under this CRADA, investigators in the Immunology and Flow Cytometry Core of NIAID's VRC and Quantum Dot Corporation will aim to adapt quantum dots for use in detailed characterization of the function and types of immune cells that respond to pathogens and vaccines. The quantum dots are semiconductor nanocrystals with unique fluorescent properties that may significantly aid in the identification of specific properties of these cells using flow cytometry.

Oligonucleotide Control Sets for Microarray Applications (Invitrogen Corporation)

The purpose of this CRADA is to develop oligonucleotide sets of standards for use as a universal reference for interpreting and reporting microarray and other expression investigative research tools. The outcome of this project should result in two complementary standard sets that can be used for researchers: (1) oligonucleotide probe sets for use by facilities that produce custom or spotted DNA microarrays, and (2) premixed cocktails of target RNA standards and hybridization controls for researchers who perform the sample labeling and hybridization of

microarrays. It is envisioned that these standards would benefit public health by facilitating the use of microarrays in biomedical research areas, including infectious diseases and genetic research as well as other research fields.

A Study of the Mechanism of Action of the Anti-HIV Compound, PA-457 (Panacos, Inc.)

NIAID and Panacos Pharmaceuticals, Inc., are collaborating under this CRADA to study the HIV inhibitory mechanism of action of Panacos Pharmaceuticals' proprietary compound PA-457. The parties will employ state-of-the-art biochemical and structural biology techniques to carry out their research program.

New CRADAs

During FY 2003, NIAID scientists entered into the following five new CRADAs:

Collaborator

GenVec, Inc.

Investigator

Phillip Gomez III, Ph.D., M.B.A.
Vaccine Research Center

Title

Evaluation of Adenoviral Encoding Proteins
Associated With SARS

Collaborator

Innogenetics

Investigator

Robert H. Purcell, M.D.
Laboratory of Infectious Diseases

Title

Analysis of the Immune Response to Hepatitis
C Virus

Collaborator

Invitrogen Corp.

Investigators

Thomas Kindt, Ph.D.
Michael Wilson, Ph.D.
Research Technologies Branch, Division of
Intramural Research

Title

Oligonucleotide Control Sets for Microarray
Applications

Collaborator

Panacos, Inc.

InvestigatorEric Freed, Ph.D.
Laboratory of Molecular Microbiology**Title**A Study of the Mechanism of Action of the
Anti-HIV Compound, PA-457**Collaborator**

Quantum Dot Corp.

InvestigatorMario Roederer, Ph.D.
Vaccine Research Center**Title**Use of Quantum Dots for Improved Cellular
Classification in Flow Cytometry**CRADAs in Effect, FY 2003****Collaborator**

Achillion Pharmaceuticals

InvestigatorJohn Inman, Ph.D.
Laboratory of Immunology**Title**Development of Optimized Inhibitors of Protein
Zinc Finger Domains**Collaborator**

American Cyanamid

InvestigatorBrian Murphy, M.D.
Laboratory of Infectious Diseases**Title**Development of Safe and Effective Live
Attenuated Vaccines for Respiratory Syncytial
Virus Subgroups A and B and Parainfluenza
Viruses Type 1, 2, and 3**Collaborator**

Biospace.com

InvestigatorLaurence Wolfe, Ph.D.
Office of Technology and Information Systems**Title**Development of an Electronic Procurement
System for Commodity Identification, Product
and Service Acquisition, and Budget Tracking**Collaborator**

Chiron

InvestigatorH. Clifford Lane, M.D.
Laboratory of Immunoregulation**Title**Research and Development of IL-2 as a
Treatment for HIV Infection

Collaborator

Ciphergen Biosystems

Investigators

John Kehrl, M.D.

Tae-Wook Chun, Ph.D.

Laboratory of Immunoregulation

Title

Identification and Characterization of Novel Non-Cytolytic Antiviral Factors Derived From CD8+ T Cells of HIV-Infected Individuals Using the ProteinChip® System

Collaborator

Connaught Technology Corp.

Investigator

Warren Strober, M.D.

Laboratory of Clinical Investigation

Title

Development of Vectored Vaccines and Therapeutics for the Prevention and Treatment of AIDS

Collaborator

Crucell

Investigator

Phillip Gomez III, Ph.D., M.B.A.

Vaccine Research Center

Title

Development of an Improved Recombinant Adenovirus Vector for Vaccination Against the Ebola Virus

Collaborator

Genetics Institute

Investigator

Ethan Shevach, M.D.

Laboratory of Immunology

Title

Analysis of Gene Expression in Immunoregulatory T Cells that Co-Express the CD4 and CD25 Surface Markers

Collaborator

Genetics Institute

Investigators

Stephen Straus, M.D.

Warren Strober, M.D.

Peter Mannon, M.D.

Ivan Fuss, M.D.

Laboratory of Clinical Investigation

Title

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Levels of Subcutaneously Administered Human Monoclonal Antibody to Interleukin-12 (J695) in Patients With Active Crohn's Disease

Collaborator

Genetics Institute

Investigator

Thomas Wynn, Ph.D.

Laboratory of Parasitic Disease

Title

Development of IL-13 Antagonism as a Treatment for Fibrosis in Schistosomiasis

Collaborator

GenVec

InvestigatorPhillip Gomez III, Ph.D., M.B.A.
Vaccine Research Center**Title**Evaluation of Adenoviral Encoding Proteins
Associated With SARS**Collaborator**

GenVec

InvestigatorPhillip Gomez III, Ph.D., M.B.A.
Vaccine Research Center**Title**Evaluation of Adenoviral Vectors Encoding
HIV-1 Proteins**Collaborator**

Glaxo Research & Development

InvestigatorClifton Barry III, Ph.D.
Laboratory of Host Defenses**Title**Development of New Drugs for the Treatment
of Tuberculosis**Collaborator**

GlaxoSmithKline

InvestigatorDavid Klein, Ph.D.
Division of Microbiology and
Infectious Diseases**Title**

Adult Pertussis Vaccine

Collaborator

GlaxoSmithKline

InvestigatorsHolli Hamilton, M.D., M.P.H.
Barbara Savarese, R.N.
Division of Microbiology and
Infectious Diseases**Title**A Double-Blind, Randomized, Controlled
Phase III Study to Assess the Prophylactic
Efficacy of rgD/Alum/MPL Vaccine in the
Prevention of Genital Herpes Disease in Young
Sexually Active Women**Collaborator**

GlaxoSmithKline

InvestigatorRobert H. Purcell, M.D.
Laboratory of Infectious Diseases**Title**

Hepatitis C Vaccine

Collaborator

GlaxoSmithKline

InvestigatorRobert H. Purcell, M.D.
Laboratory of Infectious Diseases**Title**

Hepatitis E Vaccine

Collaborator

Ichor Medical Systems

InvestigatorPhillip Gomez III, Ph.D., M.B.A.
Vaccine Research Center**Title**Evaluation of Electroporation-Mediated
Delivery of an HIV DNA Vaccine

Collaborator

Innogenetics

Investigator

Robert H. Purcell, M.D.
Laboratory of Infectious Diseases

Title

Analysis of the Immune Response to Hepatitis
C Virus

Collaborator

Invitrogen Corp.

Investigators

Thomas Kindt, Ph.D.
Michael Wilson, Ph.D.
Research Technologies Branch,
Division of Intramural Research

Title

Oligonucleotide Control Sets for Microarray
Applications

Collaborator

Lederle-Praxis
Biologicals Division
American Cyanamid

Investigator

Peter Collins, Ph.D.
Laboratory of Infectious Diseases

Title

Production of Live Attenuated RSV and PIV
Vaccine Viruses From cDNA

Collaborator

Maxygen

Investigator

Louis Miller, M.D.
Laboratory of Parasitic Disease

Title

Novel, Polyspecific Malaria Vaccine
Development Based on PfEMP1 Using
Molecular Breeding™ Directed Molecular
Evolution Technologies

Collaborator

MedImmune Vaccines (formerly Aviron)

Investigator

Ann Ginsberg, M.D., Ph.D.
Division of Microbiology and
Infectious Diseases

Title

Development of a Live Attenuated Cold-
Adapted Influenza Vaccine

Collaborator

Merck

Investigator

Gary Nabel, M.D., Ph.D.
Vaccine Research Center

Title

Development of an Adenoviral-Based HIV
Vaccine

Collaborator

Merck

Investigator

Stephen Straus, M.D.
Laboratory of Clinical Investigation

Title

A Double-Blind, Placebo-Controlled Study of the Efficacy of Live Attenuated Oka/Merck Varicella Zoster Vaccine in Reducing the Incidence and/or Severity of Shingles in Adults

Collaborator

Merial

Investigator

José Ribeiro, M.D., Ph.D.
Laboratory of Parasitic Disease

Title

Evaluation of DNA Vaccines Encoding Sand Fly Salivary Proteins as Candidates to Control Leishmania Infantum Infection in Dogs

Collaborator

Nexell Therapeutics

Investigators

Harry L. Malech, M.D.
Mitchell Horwitz, M.D.
Laboratory of Host Defenses

Title

Study of Low Intensity Preparative Regimen Followed by HLA-Matched Transplantation for Chronic Disease

Collaborator

Novartis

Investigator

Marshall Plaut, M.D.
Division of Allergy, Immunology,
and Transplantation

Title

A Double-Blind, Placebo-Controlled Study of the Efficiency of E25 anti-IgE Reducing Asthma Symptoms in Inner-City Children

Collaborator

Novavax

Investigator

Louis Miller, M.D.
Laboratory of Parasitic Disease

Title

Merozoite Surface Protein 1 Expressed in Insect Cells: Process Development, Preclinical and Initial Clinical Evaluation

Collaborator

Osel

Investigator

Edward Berger, Ph.D.
Laboratory of Viral Diseases

Title

SCD4-17b Expressed by/on Lactobacillus as an Anti-HIV Topical Microbicide

Collaborator

Panacos

Investigator

Eric Freed, Ph.D.

Laboratory of Molecular Microbiology

Title

A Study of the Mechanism of Action of the
Anti-HIV Compound, PA-457

Collaborator

Quantum Dot Corporation

Investigator

Mario Roederer, Ph.D.

Vaccine Research Center

Title

Use of Quantum Dots for Improved Cellular
Classification in Flow Cytometry

Collaborator

Wyeth-Lederle Vaccines, American Home
Products

Investigator

Pamela McInnes, Ph.D.

Division of Microbiology and
Infectious Diseases

Title

Preventing Childhood Mortality—An Efficacy
Trial of a Pneumococcal Conjugate Vaccine in
Upper and Central River Divisions, The
Gambia

NIH EXTRAMURAL FUNDING MECHANISMS USED BY NIAID

Fellowship Programs

- F31** Predoctoral Individual National Research Service Award (NRSA)—provides predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.).
- F32** Postdoctoral Individual NRSA—provides postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
- F33** NRSA for Senior Fellows—provides opportunities for experienced scientists to make major changes in the direction of their research careers, to broaden their scientific background, or to acquire new research capabilities.
- F35** Intramural NRSA Individual Postdoctoral Program—supports a postdoctoral trainee in the NIH intramural program.

Research Career Programs

- K02** Independent Scientist Award—provides support for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers.
- K08** Clinical Investigator Award—provides the opportunity for promising medical scientists (with demonstrated aptitude to develop into independent investigators) or faculty members who will pursue research aspects of categorical areas applicable to the awarding unit, and aids

in filling the important academic faculty gap in these shortage areas within health professional institutions of the country.

- K22** Career Transition Award—provides support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment of the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.
- K23** Mentored Patient-Oriented Research Career Development Award—provides support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.
- K24** Midcareer Investigator Award in Patient-Oriented Research—provides support for experienced clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators.
- K25** Mentored Quantitative Research Career Development Award—supports junior-faculty-level investigators with quantitative scientific and engineering backgrounds outside of biology or medicine who have the potential to integrate their expertise with biomedicine

and to develop into productive investigators with a period of mentored study and research.

- K30** Clinical Research Curriculum Award (CRCA)—awarded to institutions to stimulate the inclusion of high-quality, multidisciplinary didactic training as part of the career development of clinical investigators. This award is intended to support the development of new didactic programs in clinical research at institutions that do not currently offer such programs or in institutions with existing didactic programs in clinical research to support or expand their programs or to improve the quality of instruction.

Research and Development-Related Contracts

- N01** Research and Development Contract—develops or applies new knowledge or tests, screens, or evaluates a product, material, device, or component for use by the scientific community.

Research Program Projects and Centers

- P01** Research Program Project—provides a qualified institution, on behalf of a principal investigator, with the support of a broad-based, multidisciplinary, often long-term research program with a particular major objective or theme. A program project involves the organized efforts of groups of investigators who conduct research projects related to the overall program objective. The grant can provide support for the projects and for certain shared resources necessary for the total research effort. Each project supported under a program project grant

is expected to contribute to the overall program objective.

- P30** Center Core Grant—supports shared resources and facilities for categorical research by a number of investigators from different disciplines who provide a multidisciplinary approach to a joint research effort or from the same discipline who focus on a common research problem. Although funded independently of the center’s component projects or program projects, the core grant relates integratively to them. By providing more accessible resources, this support is expected to ensure greater productivity than that obtained from the separate projects and program projects.

- P50** Specialized Center—supports any part of the full range of R&D, from basic to clinical, and may involve ancillary supportive activities, such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These grants differ from program project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.

Research Project Grants and Grants Related to Research Projects

- R01** Research Project Grant (traditional)—provides support to an institution (domestic or foreign) on behalf of a principal investigator for a discrete

- project related to the investigator's interests and competence. Most of the research that the NIH supports is maintained through this funding mechanism. Although rare, such a grant may be awarded directly to an individual.
- R03** Small Grant—provides research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are nonrenewable.
- R09** Scientific Evaluation—provides the chairman of an initial review group funds for operation of the initial review group.
- R13** Conference Grant—provides funding for conferences to coordinate, exchange, and disseminate information related to program interests. In general, such awards are modest and limited to participation with other organizations in the support of conferences rather than as a provision of sole support. Among the costs eligible for support are salaries, equipment rental, travel, consultant services, and supplies. Prospective applicants should inquire in advance concerning possible interest on the part of an Institute.
- R15** Academic Research Enhancement Award (AREA)—provides support to scientists at eligible domestic institutions for small-scale, new, or expanded health-related research projects, such as pilot research projects and feasibility studies; development, testing, and refinement of research techniques; secondary analysis of available data sets; and similar discrete research projects that demonstrate research capability. This award is directed toward smaller, less-prominent 4-year public and private colleges and universities that provide undergraduate training for a significant number of U.S. research scientists but have not had an adequate share in the growth of the NIH extramural program.
- R18** Research Demonstration and Dissemination Project—provides support to develop, test, and evaluate health-service activities and to foster the application of existing knowledge for the control of categorical diseases.
- R21** Exploratory/Developmental Grant—used by NIAID for bridge awards. The bridge award provides support for a limited time and amount to investigators to enable them to continue meritorious research and improve the competitiveness of future grant applications.
- R24** Resource-Related Research Project—supports research projects that will enhance the capability of resources to serve biomedical research.
- R25** Education Project—provides support to develop or implement a program in education, information, training, technical assistance, coordination, or evaluation.
- R33** Exploratory and Developmental Grants, Phase II—provide a second phase of support for innovative, exploratory, and developmental research begun as an R21 award. Only R21 awardees are eligible to apply for R33 support. Applications are accepted only in response to RFAs and PAs that specify the R33 mechanism.

R37 Method to Extend Research in Time (MERIT) Award—provides long-term, stable support to investigators who are likely to continue to perform in an outstanding manner and spares them the administrative burdens associated with preparing and submitting research grant applications. An initial 5-year award is accompanied by an opportunity for a 3- to 5-year extension, based on an expedited review of the accomplishments during the initial award period. Investigators may not apply for a MERIT award. NIH staff and advisors base their selection of MERIT award recipients on competing R01 applications, prepared and submitted in accordance with NIH procedures. MERIT awards are awarded to a limited number of selected investigators who have demonstrated superior competence and outstanding productivity during previous research endeavors.

Small Business Funding Opportunities

- R41** Small Business Technology Transfer
R42 (STTR) Grants—support cooperative R&D projects between small business concerns and research institutions, limited in time and amount, to establish the technical merit and feasibility of ideas that have potential for commercialization. Awards are made to small business concerns only.
- R43** Small Business Innovation Research
R44 (SBIR) Grants—enable small businesses possessing technological expertise to contribute to the R&D mission of the NIH. Phase I (R43) grants support projects, limited in time and amount, to establish the technical merit and

feasibility of R&D ideas that ultimately may lead to commercial products or services. Phase II (R44) grants support indepth development of R&D ideas whose feasibility has been established in phase I and that are likely to result in commercial products or services. The research must be conducted in the United States.

Research Training Programs

- T32** Institutional NRSA—enables institutions to grant NRSAs for predoctoral and postdoctoral research training in specified shortage areas to individuals selected by the institutions.
- T35** NRSA Short-Term Research Training—provides individuals with research training during off-quarters or summer periods to encourage research careers or research in areas of national need.

Cooperative Agreements

- U01** Research Project (Cooperative Agreement)—provides an assistance relationship between the NIH and a recipient, but with substantial programmatic involvement by the NIH. The NIH assists, supports, or stimulates the recipients and is involved substantially with recipients in conducting projects similar in program content to those for grants, with the NIH playing a “partner” role in the effort.
- U19** Research Program (Cooperative Agreement)—supports a research program of multiple projects directed toward a specific major objective, basic theme, or program goal that requires a broad-based, multidisciplinary, and often long-term approach.

- U24** Resource-Related Research Projects/Cooperative Agreements—support research projects contributing to improvement of the capability of resources to serve biomedical research.
- U42** Animal (Mammalian and Nonmammalian) Model and Animal and Biomedical Materials Resource Cooperative Agreements (NCRR)—develop and support an animal (mammalian and nonmammalian) model or animal or biological materials resources available to all qualified investigators without regard to the scientific disciplines or disease orientations of their research activities or specifically directed to a categorical program. Nonmammalian resources include nonmammalian vertebrates, invertebrates, cell systems, and nonbiological systems.
- U54** Specialized Centers Cooperative Agreements—support research and development from basic to clinical, including ancillary supportive activities that create a multidisciplinary focus on a disease or a biomedical problem. Centers also may serve as regional or national resources for special research purposes.
- U56** Exploratory Grants Cooperative Agreements—support planning for new programs, expansion or modification of existing resources, and feasibility studies

for interdisciplinary programs that may lead to specialized or comprehensive centers.

- UC1** NIH Challenge Grants and Partnerships Program, Phase II, Cooperative Agreements (NIAID)—promote joint ventures between the NIH and both domestic and global entities to facilitate rapid biomedical or biotechnology R&D for infectious diseases to benefit public health; projects should have a commercial potential that could not have been attained without matching funds.

Interagency and Intra-Agency Agreements

- Y01** NIH Interagency Agreement—provides a written reimbursable agreement by which a component of the NIH provides a source of funds to another Federal organization outside DHHS to acquire specific products, services, or studies.
- Y02** NIH Intra-agency Agreement—provides a written reimbursable agreement by which a component of the NIH provides funds to another NIH component or to another organization within DHHS to acquire specific products, services, or studies.

ACRONYMS

AACTG	Adult AIDS Clinical Trials Group
AADRC	Asthma and Allergic Diseases Research Center
ABC	Actions for Building Capacity
ACE	Autoimmunity Centers of Excellence
ADAMHA	Alcohol, Drug Abuse, and Mental Health Administration
ADCC	Autoimmune Diseases Coordinating Committee
ADMO	Associate Director for Management and Operations
ADV	adenoviral vector-based
AfCS	Alliance for Cellular Signaling
AIDS	acquired immunodeficiency syndrome
AIEDRP	Acute HIV Infection and Early Disease Research Program
AIT	allergen immunotherapy
ALT	alanine aminotransferase
AREA	Academic Research Enhancement Award
ART	antiretroviral therapy
ASIR	Richard M. Asofsky Scholars In Research
ATCC	American Type Culture Collection
AVRWG	AIDS Vaccine Research Working Group
AZT	zidovudine
BAMBU	Bacteriology and Mycology Biostatistical Unit
BAMSG	Bacteriology and Mycology Study Group
BISC	Bioinformatics Integration Support Contract
BSC	Board of Scientific Counselors
BSE	bovine spongiform encephalopathy or “mad cow” disease
BSL	biosafety level
BTEP	BioTechnology Engagement Program
CASG	Collaborative Antiviral Study Group
CCTAT	Cooperative Clinical Trials in Adult Kidney Transplantation

CCTPT	Cooperative Clinical Trials in Pediatric Kidney Transplantation
CDA	Confidential Disclosure Agreement
CDC	Centers for Disease Control and Prevention
CFAR	Center for AIDS Research
CIPRA	Comprehensive International Program of Research on AIDS
CJD	Creutzfeldt-Jakob disease
CMB	Contract Management Branch
CMS	Centers for Medicare & Medicaid Services
CMV	cytomegalovirus
CPCRA	Terry Beirn Community Programs for Clinical Research on AIDS
CRADA	Cooperative Research and Development Agreement
CRC	Cooperative Research Center
CRCA	Clinical Research Curriculum Award
CRDF	Civilian Research and Development Foundation
CTA	Clinical Trial Agreement
CTL	cytotoxic T lymphocyte
CWD	chronic wasting disease
DAIDS	Division of Acquired Immunodeficiency Syndrome, NIAID
DAIT	Division of Allergy, Immunology, and Transplantation, NIAID
DARPA	Defense Advanced Research Projects Agency
DEA	Division of Extramural Activities, NIAID
DEN4	dengue virus type 4
DHHS	Department of Health and Human Services
DIR	Division of Intramural Research, NIAID
DMID	Division of Microbiology and Infectious Diseases, NIAID
DNA	deoxyribonucleic acid
DoD	Department of Defense
DOE	Department of Energy
DSA	Drug Screening Agreement

ED	emergency department
EF	edema factor
EIR	Employee Invention Report
ELISA	enzyme-linked immunosorbent assay
EPA	Environmental Protection Agency
ESPRIT	Evaluation of Subcutaneous Proleukin in a Randomized International Trial
ESRD	end-stage renal disease
FDA	Food and Drug Administration
FIC	Fogarty International Center
FOIA	Freedom of Information Act
FY	fiscal year
GAVI	Global Alliance for Vaccines and Immunization
GM-CSF	granulocyte-macrophage colony-stimulating factor
GP	glycoprotein
GSK	GlaxoSmithKline
HAART	highly active antiretroviral therapy
HAV	hepatitis A virus
HBV	hepatitis B virus
HC CRCs	Hepatitis C Cooperative Research Centers
HCV	hepatitis C virus
HEV	hepatitis E virus
HIV	human immunodeficiency virus
HIV+	HIV positive
HIVRAD	HIV Vaccine Research and Design Program
HLA	human leukocyte antigen
HOPE	Health Omnibus Programs Extension
HPIV3	human parainfluenza type 3
HPTN	HIV Prevention Trials Network

HPV	human papillomavirus
HSC	hematopoietic stem cell
HSV	herpes simplex virus
HVDDT	HIV Vaccine Design and Development Teams
HVTN	HIV Vaccine Trials Network
ICAC	Inner-City Asthma Consortium
ICBG	International Cooperative Biodiversity Groups Program
ICDs	Institutes, Centers, and Divisions
ICER	International Center for Excellence in Research
ICIDR	International Collaboration in Infectious Disease Research
ICs	Institutes and Centers
ICTDR	International Centers for Tropical Disease Research
ICU	intensive care unit
IDF	Immune Deficiency Foundation
IGIV	intravenous immunoglobulin
IHWG	International Histocompatibility Working Group
IL-2	interleukin-2
IL-4	interleukin-4
IND	investigational new drug
INRO	Intramural NIAID Research Opportunities
IOM	Institute of Medicine
IPCAVD	Integrated Preclinical/Clinical AIDS Vaccine Development Program
IPCP	Integrated Preclinical/Clinical Program
IRTA	Intramural Research and Training Awardees
ISAAC	International Studies of AIDS-Associated Co-infections
IT	immunotherapy
ITN	Immune Tolerance Network
JDRF	Juvenile Diabetes Research Foundation International
JEV	Japanese encephalitis virus

KNCV	Royal Netherlands TB Association
LF	lethal factor
<i>M.tb</i>	<i>Mycobacterium tuberculosis</i>
MACS	Multicenter AIDS Cohort Study
MADGC	Multiple Autoimmune Disease Genetics Consortium
M-CRADA	Materials Cooperative Research and Development Agreement
MDR-TB	multidrug-resistant tuberculosis
MEP	multi-epitope peptide
MERIT	Method to Extend Research in Time
MGC	Mammalian Gene Collection
MHC	major histocompatibility complex
MIM	Multilateral Initiative on Malaria
MR4	Malaria Research and Reference Reagent Resource
MRI	magnetic resonance imaging
MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
MRTC	Malaria Research and Training Center
MRU	Microbiology Research Unit
MS	multiple sclerosis
MSG	Mycoses Study Group
MSM	men who have sex with men
MTA	Material Transfer Agreement
MTCT	mother-to-child transmission
MVA	modified vaccinia Ankara virus
MVDB	Malaria Vaccine Development Branch
NAAIDC	National Advisory Allergy and Infectious Diseases Council
NARAC	North American Rheumatoid Arthritis Consortium
NARSA	Network on Antimicrobial Resistance in <i>Staphylococcus aureus</i>
NBL	National Biocontainment Laboratory
NCDDG-TB	National Cooperative Drug Discovery Groups for Tuberculosis

NCICAS	National Cooperative Inner-City Asthma Study
NCRR	National Center for Research Resources
NHIS	National Health Interview Survey
NHLBI	National Heart, Lung, and Blood Institute
NIAID	National Institute of Allergy and Infectious Diseases
NICHD	National Institute of Child Health and Human Development
NIDA	National Institute on Drug Abuse
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS	National Institute of Environmental Health Sciences
NIGMS	National Institute of General Medical Sciences
NIH	National Institutes of Health
NK	natural killer [cells]
NMR	nuclear magnetic resonance
NNIS	National Nosocomial Infections Surveillance
NRSA	National Research Service Award
NVP	nevirapine
NVPO	National Vaccine Program Office
OAS	Office of Administrative Services, NIAID
OCPL	Office of Communications and Public Liaison, NIAID
OCR	Office of Clinical Research, NIAID
OD	Office of the Director, NIAID
OE	Office of Ethics, NIAID
OFM	Office of Financial Management, NIAID
OHRM	Office of Human Resources Management, NIAID
OI	opportunistic infection
OMNI	Office of Management for New Initiatives, NIAID
ONR	Office of Naval Research
OPA	Office of Policy Analysis, NIAID
OSPRT	Office of Special Populations and Research Training, NIAID
OTD	Office of Technology Development, NIAID

OTIS	Office of Technology Information Systems, NIAID
OTSEP	Office of Training and Special Emphasis Programs
OTT	Office of Technology Transfer, NIH
PA	program announcement
PACTG	Pediatric AIDS Clinical Trials Group
PAVE	Partnership for HIV/AIDS Vaccine Evaluation
PCR	polymerase chain reaction
PFGRC	Pathogen Functional Genomics Resource Center
PID	pelvic inflammatory disease
PIDR	Primary Immunodeficiency Diseases Registry
PIV	parainfluenza virus
PMN	polymorphonuclear neutrophil
PMPA	9-(2-phosphonylmethoxypropyl)-adenine
PR	protease
PRP	polyribosylribose phosphate
PrP	prion protein
PrP-res	abnormal form of prion protein
R&D	research and development
RBL	Regional Biocontainment Laboratory
RCE	Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases
RCMI	Research Centers in Minority Institutions
RFA	request for application
RIT	rush immunotherapy
RML	Rocky Mountain Laboratories
RNA	ribonucleic acid
rPA	recombinant protective antigen vaccine
RPAB	Referral and Program Analysis Branch
RPG	Research Project Grant
RSUM	Research Supplements for Underrepresented Minorities

RSV	respiratory syncytial virus
RT	reverse transcriptase
SAIC	Science Applications International Corporation
SARS	severe acute respiratory syndrome
SARS-CoV	SARS-associated coronavirus
SBIR	Small Business Innovation Research
SCID	severe combined immunodeficiency disease
SIV	simian immunodeficiency virus
SLE	systemic lupus erythematosus
SLEV	St. Louis encephalitis virus
SMART	Strategies for Management of Anti-Retroviral Therapies
SNP	single nucleotide polymorphisms
SPR	Summer Policy Retreat
SRP	Scientific Review Program
STD	sexually transmitted disease
STI	sexually transmitted infection
STTR	Small Business Technology Transfer
SVEU	Simian Vaccine Evaluation Unit
TAACF	Tuberculosis Antimicrobial Acquisition and Coordinating Facility
TB	tuberculosis
TBRU	Tuberculosis Research Unit
TEAC	Technology Evaluation Advisory Committee
TIGR	The Institute for Genomic Research
TMP-SMX	trimethoprim-sulfamethoxazole
TMRC	Tropical Medicine Research Center
TSE	transmissible spongiform encephalopathy
USAID	U.S. Agency for International Development
USAMRIID	U.S. Army Medical Research Institute of Infectious Diseases
USAMRMC	U.S. Army Medical Research and Materiel Command
USJCMSP	U.S.-Japan Cooperative Medical Science Program

VAP	Vaccine Action Program
VDF	Vaccine Development Facility
VPP	Vaccine Pilot Plant
VRC	Dale and Betty Bumpers Vaccine Research Center
VRE	vancomycin-resistant enterococci
VTEU	Vaccine and Treatment Evaluation Unit
WHO	World Health Organization
WIHS	Women's Interagency HIV Study
WITS	Women and Infants Transmission Study
WNV	West Nile virus
WPR	Winter Program Review
YFV	yellow fever virus

INDEX

A

- abnormal form of prion protein (PrP-res) 88, 212
- Academic Research Enhancement Award (AREA) iii, 14, 17, 19, 22, 26, 37, 47, 48, 54, 73, 79, 84, 99, 104, 111, 116, 152, 202-203, 206, 230
- Acambis, Inc. 83
- acquired immunodeficiency syndrome (AIDS) i-vi, 2, 6-7, 9-16, 23, 25, 27, 29-30, 35, 38-39, 41-44, 47, 69-71, 73, 76, 78, 82, 99, 100-102, 104, 113-119, 124, 126, 130, 133, 135, 139-142, 150, 154, 160-161, 163, 165-171, 184-185, 190, 196, 201, 206-207, 209-210, 212, 229
- Acquired Immunodeficiency Syndrome Research Review Committee vi, 166
- Actions for Building Capacity (ABC) 206
- Acute HIV Infection and Early Disease Research Program (AIEDRP) 13, 206
- adenoviral vectors (ADV) 33, 64, 206
- Adult AIDS Clinical Trials Group (AACTG) 13, 71, 115, 119-120, 206
- Aedes aegypti* 98
- agreements 4, 36-37, 86-87, 102, 163, 166, 176, 192-193, 204-205
- AIDS Research Advisory Committee vi, 38, 168, 170
- AIDS Research and Reference Reagent Program 12, 16, 82, 104, 154
- AIDS Vaccine Research Working Group (AVRWG) 140, 206
- AIDS. *See* acquired immunodeficiency syndrome
- alanine aminotransferase (ALT) 206
- Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) 184, 206
- allergen immunotherapy (AIT) 53, 206
- allergy i-vi, 1-232
- Allergy, Immunology, and Transplantation Research Committee vi, 173
- Alliance for Cellular Signaling (AfCS) 67, 206
- American Type Culture Collection (ATCC) 206
- Animal (Mammalian and Nonmammalian) Model and Animal and Biomedical Materials Resource Cooperative Agreements 205
- Anopheles gambiae* 91, 98
- anthrax 9-10, 21, 57, 59, 62, 64-65, 77-78, 80, 90, 99, 155
- antimicrobial drug resistance 22, 160
- antiretroviral therapy (ART) 26, 31-32, 34, 41-42, 44-45, 55, 59, 61, 80, 96, 107, 119-120, 131, 154, 159, 194, 206
- antiviral agents 60, 69, 72, 87, 157
- arbovirus 158
- Arthritis Foundation 55, 97, 155
- arthritis ii, iii, 1, 55, 56, 74, 94, 95, 97, 106, 107, 155, 191, 210
- ASIR. *See* Richard M. Asofsky Scholars In Research
- Aspergillus fumigatus* 98
- Associate Director for Management and Operations (ADMO) 206, 225
- Asthma and Allergic Diseases Research Center (AADRC) 206
- asthma i, iii, v, 2, 6, 17, 18, 19, 25, 27, 50, 51, 52, 53, 54, 74, 75, 94, 95, 96, 106, 107, 111, 112, 130, 160, 161, 174, 199, 206, 209, 211, 228
- atopic dermatitis 50, 57
- Autoimmune Diseases Coordinating Committee (ADCC) 54, 112, 121, 206
- autoimmune diseases iii, v, 10, 17-19, 26, 54, 55, 56, 74-75, 95-97, 106, 112, 118, 120, 121, 130-131, 136, 148, 155, 206
- Autoimmunity Centers of Excellence (ACE) 54, 96, 121, 206
- Aviron 87, 198
- awards vi, 8, 25, 36, 37, 59, 60, 80, 97, 100, 101, 116, 117, 126, 140, 147, 163, 166, 173, 176, 187, 191, 203, 204
- azithromycin 74, 122
- AZT. *See* zidovudine

B

- Bacillus anthracis*. *See* anthrax
- Bacillus cereus* 91
- bacterial vaginosis 124
- bacteriology 2, 20, 47, 73, 176, 206, 228
- Bacteriology and Mycology Biostatistical Unit (BAMBU) 73, 206
- Bacteriology and Mycology Study Group (BAMSG) 73, 206
- bilateral programs 102
- Biodefense and Emerging Infections Research Resources Program 80
- Biodefense Partnerships 59
- Biodefense Research Agenda for CDC Category A Agents i-10
- biodiversity 102, 209

- bioengineering v,1,66
 biofilms 48-49
 Bioinformatics Integration Support Contract (BISC) 68, 206
 bioinformatics v, 5, 31, 60, 66, 68, 94, 95, 96, 107, 159, 206
 biology of the microbe 62
 biosafety level (BSL) 26, 61, 79-80, 88, 206
 BioTechnology Engagement Program (BTEP) 206
 Blue Ribbon Panel on Genomics 24
 Board of Scientific Counselors (BSC) 28, 206
 borreliosis 78, 85
 bovine spongiform encephalopathy, or “mad cow” disease (BSE) 88, 206
 breastfeeding 15, 42-43, 120
Brucella suis 58, 91
Brugia malayi 98
 bubonic plague 62
 budget iii, vi, 4, 8, 9, 36-38, 99, 101, 178, 183,-187, 192, 195
 BufferGel® 127
Burkholderia mallei 58, 78, 91
- C**
- canarypox 143
 capsid 40-41, 151-152
 carcinogenesis 102
 career development awards 37
 Career Transition Award 201
 Category A, B, C agents 21, 57, 74, 80
 CD25 196
 CD4+ T cells 40, 45
 Center Core Grant 202
 Center for AIDS Research (CFAR) 12, 101, 207
 Centers for Disease Control and Prevention (CDC) i-10, 23, 39, 42, 48, 73, 78-79, 82, 87, 103, 114, 142, 145, 160-161, 207
 Centers for Medicare & Medicaid Services (CMS) 120, 207
 Chagas’ disease 98
 chlamydia 24, 68, 90, 114, 121, 124, 139, 144
 chronic fatigue syndrome 118, 190
 chronic wasting disease (CWD) 88-89, 207
 cidofovir 60
 CIPRA. *See* Comprehensive International Program of Research on AIDS
 Civilian Research and Development Foundation (CRDF) 207
 Clinical Investigator Award 201
 Clinical Research Curriculum Award (CRCA) 202, 207
 clinical studies 13, 15, 23, 41, 45, 48, 51, 70, 73, 85, 87, 113, 118, 126, 135
 Clinical Trial Agreement (CTA) 207
 clinical trials 2, 7, 13-16, 18-22, 29-35, 45, 47, 53-55, 59, 63, 71, 73-75, 83, 87, 96, 102, 107, 109-111, 113-116, 119, 121, 123-125, 127-129, 133, 135, 137, 141-142, 144, 146, 148-150, 152, 155, 206-207, 212, 226-227
Clostridium botulinum 78
Clostridium perfringens 58, 78, 91, 98
Coccidioides immitis 78, 98
 Collaborative Antiviral Study Group (CASG) 60, 73, 206
 Committee Management Office 2, 38
 Community Programs for Clinical Research on AIDS 13, 16, 44, 71, 115, 190, 207
 Comprehensive International Program of Research on AIDS (CIPRA) 15, 101-102, 135, 207
 computer linkages 26
 Conference Grant 203
 Confidential Disclosure Agreement (CDA) 207
 Contract Management Branch (CMB) 36, 207, 229
 cooperative agreement 204
 Cooperative Centers for Translational Research on Human Immunology and Biodefense 58, 147
 Cooperative Clinical Trials in Adult Kidney Transplantation (CCTAT) 206
 Cooperative Clinical Trials in Pediatric Kidney Transplantation (CCTPT) 129, 207
 Cooperative Research and Development Agreement (CRADA) 5, 87, 192-194, 207, 210
 Cooperative Research Center (CRC) 207
 Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense 59
 coronavirus 33, 77-78, 81-82, 84, 93, 213
 Council News 37
Coxiella burnetii 58, 78, 91
 CPCRA. *See* Terry Beirn Community Programs for Clinical Research on AIDS
 Creutzfeldt-Jakob disease (CJD) 88, 207
 Crohn’s disease 196
 Crucell 196
Cryptococcus neoformans 98
Cryptosporidium parvum 58, 71, 79, 91, 98
 cysteine proteinase inhibitors 82

cytokine 27, 32, 62, 75, 95, 107
 cytomegalovirus (CMV) 72-73, 139, 144, 207
 cytotoxic T lymphocyte (CTL) 42, 143, 207

D

Dale and Betty Bumpers Vaccine Research Center (VRC) 6, 29-35, 63-64, 139-140, 149-150, 193, 214, 226, 230-231
 databases 68-69, 71, 90, 94-95, 109, 124
 Defense Advanced Research Projects Agency (DARPA) 91, 94, 207
 demographics, HIV/AIDS 39
 dengue vaccine 149
 dengue virus type 4 (DENV4) 207
 deoxyribonucleic acid (DNA) 24, 26, 32-34, 40, 42, 48, 53, 57, 64, 69, 83, 86, 90-91, 95-96, 105, 107, 136, 140-141, 143-144, 146, 150, 154, 159, 194, 197, 199, 207
 Department of Defense (DoD) 21, 42, 68, 141-142, 207
 Department of Energy (DOE) 91, 207
 Department of Health and Human Services (DHHS) v, 3-4, 9, 21, 102, 134, 139, 183, 190, 205, 207
 diabetes ii, iii, 1, 52, 54, 55, 56, 70, 74, 75, 94, 95, 96, 105, 106, 107, 112, 119, 129, 130, 162, 209, 211
 diagnostic tools 20, 58, 74, 80, 138
 diarrheal diseases 47
 directors 28, 103, 166, 183, 191
 Division of Acquired Immunodeficiency Syndrome, NIAID (DAIDS) 7, 11-15, 29, 33, 69, 71-73, 125, 134-135, 139-140, 150, 154, 168, 207, 226
 Division of Allergy, Immunology, and Transplantation, NIAID (DAIT) 17-19, 51, 54-55, 74-75, 94-95, 106, 108, 112, 121, 129-131, 135-136, 139, 146-147, 156, 207, 227
 Division of Computer Research and Technology 26
 Division of Extramural Activities, NIAID (DEA) 36-37, 207, 228
 Division of Intramural Research, NIAID (DIR) 25-28, 30, 44-45, 48-49, 62-65, 75-76, 81, 87-88, 105, 117-118, 136-137, 139, 148-149, 156, 178, 207, 229
 Division of Microbiology and Infectious Diseases, NIAID (DMID) 20-24, 30, 33, 35, 57, 60-61, 71-74, 77, 83, 88, 92-93, 104, 124-125, 133-134, 139, 144-146, 148, 156-157, 193, 207, 228
 DNA. *See* deoxyribonucleic acid
 DnaE2 136, 160
 drug discovery 13, 16, 20, 27, 67, 69-70, 72, 86, 135, 210

drug resistance 20, 22, 27, 43-48, 69, 90, 104, 109, 136-137, 160
 Drug Screening Agreement (DSA) 208

E

E25 anti-IgE 199
 Ebola virus 10, 33, 63-64, 150, 196
 edema factor (EF) 208
 Education Project 203
Ehrlichia spp 98
 Ehrlichiosis 78, 85, 98
 emergency department (ED) 51, 208
 emerging and re-emerging infectious diseases i, v, 21, 57, 77, 78, 81, 92, 93, 99, 102
 Emerging Viral Diseases Centers 83
 Employee Invention Report (EIR) 208
 end-stage renal disease (ESRD) 208
Entamoeba histolytica 58, 79, 91, 98
 enteric 2, 58, 80, 102, 160, 228
 enterococci 46, 214
 Environmental Protection Agency (EPA) 52, 208
 enzyme-linked immunosorbent assay (ELISA) 85, 208
Escherichia coli 91
 Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) 13, 208
 Expert Panel on Atopic Dermatitis and Vaccinia Immunization 57
 Expert Panel on Immunity and Biodefense 57
 Exploratory and Developmental Grants 203
 Exploratory Grants Cooperative Agreements 205

F

Fauci, Anthony S. iv, 163, 180, 225, 230
 filariasis 157
 fiscal year (FY) vi, 8, 18, 35, 59-60, 79-81, 83, 85, 92, 97, 99-102, 111, 113, 116-117, 129-130, 143-144, 146-147, 150, 184-187, 192-195, 208
 flaviviruses 28, 64, 84
 FluMist 22, 87
 Fogarty International Center (FIC) 100, 208
 food allergy 27, 50, 160, 164
 Food and Drug Administration (FDA) 33-35, 72-73, 76, 80, 82, 87, 208
 fowlpox 141
 Frederick Cancer Research and Development Center 26, 230
 Freedom of Information Act (FOIA) 4, 208

G

gas gangrene 98
 Gates Malaria Vaccine Initiative 109
 genomics v, 21, 23-24, 31, 59, 66, 75, 82, 90, 92-96, 133-134, 136, 159, 212
Giardia lamblia 58, 79, 91, 98
 GlaxoSmithKline (GSK) 208
 Global Alliance for Vaccines and Immunization (GAVI) 145, 208
 global health ii, v, 9, 21, 23, 78, 79, 99, 138, 156
 Global Health Research Plan for HIV/AIDS, Malaria, and Tuberculosis 9, 23, 78, 99
 glycoprotein (GP) 44, 208
 gonorrhea 22, 24, 90, 114, 121, 124, 144
 gp120 32, 143
 graft rejection 19, 55, 75, 94-96, 106, 112, 129-130
 grants iii, 2, 12, 14-16, 19, 21-23, 36-37, 39, 47-48, 59, 66, 70, 73-74, 80, 82, 85, 86, 102, 108, 110, 117, 121, 123-124, 126, 135, 137, 139-140, 147, 163, 166, 173, 176, 186, 191, 202-205, 229
 Grants Management Branch 2, 36, 229
 granulocyte-macrophage colony-stimulating factor (GM-CSF) 148, 208
 Group B *Streptococcus* 98, 139, 144

H

HAART. *See* highly active antiretroviral therapy
 health disparities 1, 10, 100, 111, 117
 Health Omnibus Programs Extension (HOPE) 29, 82, 115, 140, 168, 190, 208
 hematopoietic stem cell (HSC) 131, 209
 hemorrhagic fevers 33, 64, 72, 78, 157
 hepatitis A virus (HAV) 151, 208
 hepatitis B virus (HBV) 208
 Hepatitis C Cooperative Research Centers (HC CRCs) 208
 hepatitis C virus (HCV) 103-105, 112-113, 193, 208
 hepatitis E virus (HEV) 151-153, 208
 herpes simplex virus (HSV) 122, 140, 157, 209
 Herpevac Trial for Women 125
 highly active antiretroviral therapy (HAART) iii, 12-14, 39-41, 43-45, 69, 119-120, 130, 208
 highly active antiretroviral therapy 12, 39, 69, 119, 130, 160, 208
 histocompatibility 56, 66, 96, 131, 136, 147, 155, 209-210
Histoplasma capsulatum 98

HIV positive (HIV+) 208
 HIV Prevention Trials Network (HPTN) 15, 42-43, 101, 115, 119-120, 123, 127, 208
 HIV Vaccine Design and Development Teams (HVDDT) 14, 140-141, 209
 HIV Vaccine Developmental Resources Contracts 16
 HIV Vaccine Research and Design Program (HIVRAD) 14, 208
 HIV Vaccine Trials Network (HVTN) 14, 34-35, 101, 115, 141, 143, 150, 209
 HIV/AIDS ii, iv, 6-7, 9-12, 15, 23, 29-30, 39, 41-43, 69, 70, 71, 78, 99-102, 113-116, 118-119, 124, 135, 140-142, 160, 184, 212
 HIV/AIDS clinical trials sites 35, 45, 101-102, 106, 112-115, 123, 127, 139, 141
 human immunodeficiency virus (HIV) i-ii, iv, 2, 6-7, 9-16, 20, 23, 29, 30-32, 34, 35, 39-44
 human leukocyte antigen (HLA) 56, 112, 131, 136, 147, 199, 208
 human papillomavirus (HPV) 120, 122, 209
 human parainfluenza type 3 (HPIV3) 148, 208
 Human Resources Operations Branch 4

I

Immune Deficiency Foundation (IDF) 209
 immune response ii, iii, 12, 24, 26, 27, 31, 32, 35, 40, 41, 53, 56, 58, 63-64, 67, 79, 82, 86-87, 94, 97, 104-105, 109, 112, 120-121, 130-132, 143, 145-146, 148-150, 193-194, 198
 immune system i-iii, 11, 13, 17-19, 25-26, 29, 31, 39, 41, 43-45, 49, 53-55, 57-58, 60, 66, 67, 69, 75, 77, 94-96, 105-106, 112, 129, 130, 135, 139, 147
 immune tolerance iii, v, 19, 52, 54, 75, 94-95, 106, 108, 112, 129-131, 209
 Immune Tolerance Network (ITN) iii, 19, 52-55, 75, 95-96, 106-108, 112, 130-131, 209
 immune-based therapies 18, 52, 59, 74, 95
 immunogenetics 95, 173, 230
 immunology i, iii, v, vi, 2, 6, 14, 17-20, 22, 25-26, 29-30, 32, 34, 36, 40, 51, 53-54, 57-58, 66, 68-69, 74, 81, 85, 94, 95, 102, 106, 108, 116-117, 121, 129-130, 135, 138-140, 144, 146-147, 155-156, 160, 163-164, 166-167, 169, 171, 173-174, 177-179, 181, 193, 195-196, 199, 207, 226-230
 immunomodulation trials 19, 146
 immunostimulants 59

- immunotherapy (IT) iii, 4, 7, 14, 34-35, 40-41, 44, 53, 63, 69, 84-85, 87-88, 93, 95, 101, 107, 111, 113-115, 119, 122, 125-127, 143, 150-152, 154, 156, 158, 166, 173, 176, 194, 209
- Independent Scientist Award 201
- infectious diseases i-vi, 1-126, 132-133, 136, 139-140, 144, 146
- influenza i, 20, 22, 28, 72, 77, 79, 81-82, 86-87, 144-145, 148, 157, 161, 198
- Inner-City Asthma Consortium (ICAC) 52, 209
- Inner-City Asthma Study iii, 51, 52, 111, 211
- innovation grants 12, 14, 16, 70, 126, 140
- Innovation Grants for AIDS Research Program 12, 16, 70, 126, 140
- Institute of Medicine (IOM) 144-145, 209
- Institutes and Centers (ICs) 184, 209
- Institutes, Centers, and Divisions (ICDs) 28, 184, 209
- Institutional NRSA 204
- insulin 55, 70, 94, 107
- Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Program 14, 209
- Integrated Preclinical/Clinical Program (IPCP) 70, 209
- Integrated Preclinical/Clinical Program for HIV Topical Microbicides 16, 126
- intensive care units (ICUs) 46-47, 209
- Interagency Task Force on Antimicrobial Resistance 48
- interferons 82
- interleukin-2 (IL-2) 13, 45, 195, 209
- interleukin-4 (IL-4) 95, 209
- international agencies and organizations 102
- International Center for Excellence in Research (ICER) 100, 209
- International Centers for Infectious Diseases Research 74
- International Centers for Tropical Disease Research (ICTDR) 100, 209
- International Collaboration in Infectious Disease Research (ICIDR) 100, 209
- International Cooperative Biodiversity Groups Program (ICBG) 209
- International Histocompatibility Working Group (IHWG) 56, 96, 131, 209
- International Studies of AIDS-Associated Co-infections (ISAAC) Program 70, 160, 209
- Intramural NIAID Research Opportunities (INRO) 117-118, 209
- Intramural NRSA Individual Postdoctoral Program 201
- Intramural Research and Training Awardees (IRTA) 209
- Intramural Research Programs 62, 178
- intramural research training and collaborative research 99
- intravenous immunoglobulin (IGIV) 209
- investigational new drug (IND) 33, 126, 209
- J**
- Japan 99, 102, 213
- Japanese encephalitis virus (JEV) 209
- Jordan Report 22
- Juvenile Diabetes Research Foundation International (JDRF) 54, 56, 130-131, 209
- K**
- kidney iii, 1, 19, 52, 54, 67, 70, 75, 95-96, 105-108, 112, 129-131, 206, 207, 211
- KNCV. *See* Royal Netherlands TB Association
- Kyasanur forest disease 64
- L**
- laboratories 2, 6, 21, 25-26, 56, 60-61, 63, 76, 79-80, 85, 88, 96, 99-100, 104, 107, 109, 117-118, 121, 131, 141-142, 157-158, 178, 192, 212, 230-231
- Laboratory Methods to Assess Responses to HIV Vaccine Candidates 16
- Laboratory of Parasitic Diseases 2, 100, 230
- laboratory review process, DIR 28
- lactobacillus 199
- Langat virus 64
- Large-Scale Antibody and T cell Epitope Discovery Program 148
- Lassa virus 10, 33
- Legionella pneumophila* 98
- Legionnaire's disease 98
- legislative chronology vi, 190
- Leishmania major* 98
- leishmaniasis 98
- leprosy 102, 156-157
- lethal factor (LF) 210
- licensure 22, 34-35, 80, 124
- Liver and Pancreatic Disease in HIV Infection Program 16, 70-71
- Lyme disease 20, 22, 81, 85-86
- M**
- M.tb* 71, 79, 84, 91-92, 94, 133-137, 156, 210
- “mad cow” disease. *See* bovine spongiform encephalopathy
- magnetic resonance imaging (MRI) 67, 210

- major histocompatibility complex (MHC) 68, 136, 147-148, 155-156, 210
- malaria i, ii, v, 6, 9, 20, 22-27, 46-47, 67, 70, 72, 77-78, 91, 93, 98-100, 102, 109-110, 113, 133, 136, 139-140, 144-145, 147-149, 156, 160-162, 184, 198, 210, 230
- Malaria Research and Reference Reagent Resource (MR4) 93, 156, 210
- Malaria Research and Training Center (MRTC) 100, 210
- Malaria Vaccine Development Branch (MVDB) 109, 210, 230
- malignancies 16, 69-71, 130
- Mammalian Gene Collection (MGC) 94, 210
- Marburg virus 10, 78
- mast cells 27, 75, 95
- Material Transfer Agreement (MTA) 210
- Materials Cooperative Research and Development Agreement (M-CRADA) 210
- Maxygen 198
- men who have sex with men (MSM) 114, 210
- Mentored Patient-Oriented Research Career Development Award 201
- Mentored Quantitative Research Career Development Award 201
- merozoite surface protein 199
- methicillin-resistant *Staphylococcus aureus* (MRSA) 46, 210
- Method to Extend Research in Time (MERIT) Award 9, 127, 163, 166, 173, 176, 180, 204, 210
- MHC tetramer core facility 155-156
- microbes i, iii, 10, 20-22, 24, 25, 57- 59, 73, 90, 93, 114, 124, 159
- Microbicide Preclinical Development Program 16, 123, 126
- microbicides 11, 15-16, 42-43, 74, 101, 114-115, 121-127
- Microbicides Development and Evaluation Workshop 125
- Microbiology and Infectious Diseases Research Committee vi, 176
- Microbiology Research Unit (MRU) 80, 210
- Microchip drug delivery system 67
- Midcareer Investigator Award in Patient-Oriented Research 201
- minority health 1, 100, 111
- minority researchers' training and enhancement programs 116
- modified vaccinia virus Ankara (MVA) 35, 42, 59, 63, 141, 143, 150, 210
- monkeypox 21, 77
- mother-to-child transmission (MTCT) 13, 15, 115, 120, 210
- MSG 73, 210
- Multicenter AIDS Cohort Study (MACS) 11, 115, 154, 210
- multidrug-resistant tuberculosis (MDR-TB) 47-48, 79, 84, 137, 210
- multi-epitope peptide (MEP) 42, 210
- Multilateral Initiative on Malaria (MIM) 210
- Multiple Autoimmune Disease Genetics Consortium (MADGC) 55, 97, 155, 210
- multiple sclerosis (MS) 107, 210
- musculoskeletal and skin diseases 55, 97, 155, 191
- mutagenesis 102
- Mycobacterium smegmatis* 134
- Mycobacterium tuberculosis (M.tb)*. See *M.tb*
- mycology 2, 20, 47, 73, 176, 206, 228
- Mycoses Study Group (MSG) 73

N

- National Academy of Sciences 25, 144-145
- National Advisory Allergy and Infectious Diseases Council (NAAIDC) 36, 38, 210
- National Biocontainment Laboratory (NBL) 61, 210
- National Cancer Institute 56, 67, 71, 126, 136, 148
- National Center for Research Resources (NCRR) 184, 205, 211
- National Center on Minority Health and Health Disparities 1, 100
- National Cooperative Drug Discovery Groups for Tuberculosis (NCDDG-TB) 135, 210
- National Cooperative Drug Discovery Groups—Opportunistic Infections 16
- National Cooperative Inner-City Asthma Study (NCICAS) 52, 211
- National Health Interview Survey (NHIS) 211
- National Heart, Lung, and Blood Institute (NHLBI) 211
- National Institute of Allergy and Infectious Diseases (NIAID) i-vi, 1-12, 14-15, 17, 19-26, 28-30, 35-45, 47-48, 50-56
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 55, 97, 155, 191
- National Institute of Child Health and Human Development (NICHD) 125-126, 211

- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 54-56, 70-71, 106, 108, 130, 211
- National Institute of Environmental Health Sciences (NIEHS) 51-52, 111, 211
- National Institute of General Medical Sciences (NIGMS) 67, 94, 211
- National Institute on Drug Abuse (NIDA) 211
- National Institutes of Health (NIH) i, iv, vi, 3-6, 9-12, 15, 17, 21-23, 25-26, 28-29, 35-38, 53-54, 57, 59, 64, 73, 76-78, 82-85, 88-89, 92-94, 99-104, 109, 111-112, 116-118, 121, 123-124, 131, 133-134, 136, 140, 142, 148, 154, 160-161, 163, 166, 168, 171, 173, 176, 178, 180, 183-185, 187, 190-193, 201, 203-205, 211-212, 225-227
- National Nosocomial Infections Surveillance (NNIS) 160, 211
- National Research Service Award (NRSA) 201, 204, 211
- National Vaccine Program Office (NVPO) 145, 211
- natural killer (NK) cells 26, 45, 211
- nematode species 98
- Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) 158, 210
- neurosyphilis 124
- neutrophil 63, 212
- nevirapine (NVP) 43, 120, 211
- new drugs and therapeutic agents 13
- New Technologies for HIV and HIV Vaccine-Related Research Program 16
- North American Rheumatoid Arthritis Consortium (NARAC) 55, 97, 155, 210
- nosocomial infections 160, 211
- nuclear magnetic resonance (NMR) 211
- O**
- Office of Administrative Services, NIAID (OAS) 3, 211, 225
- Office of Clinical Research, NIAID (OCR) 211, 225
- Office of Communications and Public Liaison, NIAID (OCPL) 3, 6, 211, 225
- Office of Equal Employment Opportunity 2-3, 225
- Office of Ethics, NIAID (OE) 211, 225
- Office of Financial Management, NIAID (OFM) 211, 226
- Office of Human Resources Management, NIAID (OHRM) 211, 226
- Office of Management for New Initiatives, NIAID (OMNI) 4, 211, 226
- Office of Naval Research (ONR) 91, 211
- Office of Policy Analysis, NIAID (OPA) 211, 226
- Office of Special Populations and Research Training, NIAID (OSPRT) 37, 111, 211, 229
- Office of Technology Development, NIAID (OTD) 4-5, 192-193, 211, 226
- Office of Technology Information Systems, NIAID (OTIS) 5, 212, 226
- Office of Technology Transfer, NIH (OTT) 192, 212
- Office of the Director, NIAID (OD) 3, 111, 211, 225
- Office of Training and Special Emphasis Programs (OTSEP) 117-118, 212
- Omsk hemorrhagic fever 64
- opportunistic infection (OI) 211
- organ transplantation 111
- outreach activities v, 6, 11, 111, 115, 118
- oxazoline hydroxamic acids 72
- P**
- 9-(2-phosphonylmethoxypropyl)-adenine (PMPA) 127, 212
- pancreatic disease 16, 70-71
- Pandemic Preparedness in Asia 82, 87
- parainfluenza virus (PIV) 198, 212
- parasites iii, 2, 20, 25, 27, 46, 67, 72, 109, 149, 157, 230
- Partnership for HIV/AIDS Vaccine Evaluation (PAVE) 42, 104, 142, 212
- Pathogen Functional Genomics Resource Center (PFGRC) 92-93, 159, 212
- pathogen genomics 24
- Pediatric AIDS Clinical Trials Group (PACTG) 13, 71, 115, 119-120, 212
- pelvic inflammatory disease (PID) 212
- pertussis vaccine 101, 197
- PfEMP1 198
- plague 10, 25, 28, 62-63, 90
- planning v, 2-4, 8-12, 15, 35, 38, 42, 78, 80, 102, 121, 123, 127, 143, 205, 227
- Plasmodium falciparum* 91, 109, 149, 162
- Plasmodium vivax* 98
- PMPA. *See* 9-(2-phosphonylmethoxypropyl)-adenine
- pneumococcal reference laboratory 157
- pneumococcus 144
- pneumonia ii, 20, 22, 46, 72-73, 81, 86, 98
- policy retreats 8
- polymerase chain reaction (PCR) 212
- polymorphonuclear neutrophil (PMN) 212

polyribosylribose phosphate (PRP) 88, 157, 212
 Postdoctoral Individual NRSA 201
 poxvirus 35, 63, 68, 72, 94, 150
 Predoctoral Individual NRSA 201
 Prevention Research 2, 14-15, 39, 42-43, 100, 115, 154, 227
 Primary Immunodeficiency Diseases Registry (PIDR) 155, 212
 primates 31-33, 64, 81, 88, 127, 148, 193
 prion diseases 25, 27, 78, 81, 83, 87-88
 prion protein (PrP) 88, 157
 PRO 2000/5 Gel 127
 Profile iii
 program announcement (PA) 115, 117, 194-195, 200, 212
 program reviews 8-9
 Project EXPLORE 43
 protease (PR) 69, 212
 protease inhibitors 13, 40, 119
 Protein Zinc Finger Domains 195
 proteins 12, 20, 24-25, 32-33, 41, 57, 59, 63, 67-69, 80-83, 88, 92, 94, 135-136, 143, 147, 150, 152, 155, 159, 193-194, 197, 199
 proteomics 66, 68, 94
 PRP-res. *See* abnormal form of prion protein
 Public Health Action Plan to Combat Antimicrobial Resistance 23, 48, 73

R

reagents and reference standards 154, 157
 recombinant protective antigen vaccine (rPA) 212
 re-emerging diseases i, 21, 77-79
 references vi, 160
 Referral and Program Analysis Branch (RPAB) 37, 212, 229
 Regional Biocontainment Laboratory (RBL) 61, 212
 Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases (RCE) 60-61, 80, 212
 repositories vi, 94, 154, 157
 request for application (RFA) 48, 117, 212
 Research Agenda for Emerging Infectious Diseases 78
 research and development (R&D) 36, 186, 202, 204-205, 212
 Research Centers in Minority Institutions (RCMI) 212
 Research Demonstration and Dissemination Project 203
 Research Program Project 202
 Research Project Grant (RPG) 212

Research Supplements for Underrepresented Minorities (RSUM) 116, 212
 Resource-Related Research Project 203
 Resource-Related Research Projects/Cooperative Agreements 205
 respiratory syncytial virus (RSV) 144, 148, 198, 213
 reverse transcriptase (RT) 69, 213
 ribonucleic acid (RNA) 40, 69, 81, 151-152, 194, 212
 Richard M. Asofsky Scholars In Research (ASIR) 117, 206
Rickettsia rickettsii 98
Rickettsia typhi 58, 91, 98
 rift valley fever 10, 78
 Rocky Mountain Laboratories (RML) 85, 88-89, 212, 229-230
 Rocky Mountain spotted fever 98
 Royal Netherlands TB Association (KNCV) 210
 rush immunotherapy (RIT) 212

S

Salmonella 47, 79, 91-92, 98, 160
 SARS. *See* severe acute respiratory syndrome
 SARS-associated coronavirus (SARS-CoV) 93, 213
 schistosomiasis 157, 196
 Science Applications International Corporation (SAIC) 213
 Scientific Evaluation 203
 Scientific Review Program (SRP) 37, 213, 229
 scleroderma 55, 112, 120
 scrapie 76, 88, 161
 screening program 60, 72, 157
 severe acute respiratory syndrome (SARS) i, 21-22, 28, 30, 33, 58, 65, 72, 77-78, 81-84, 92-93, 102, 144, 192-194, 197, 213
 severe combined immunodeficiency disease (SCID) 213
 sex-based differences in the immune response 112, 121
 sexually transmitted disease (STD) 74, 124-125, 169, 213
 sexually transmitted infection (STI) 20, 23-24, 72, 74, 113-114, 118, 121-125, 213
Shigella 47, 79, 91
 short-term research training 204
 simian immunodeficiency virus (SIV) 127, 213
 Simian Vaccine Evaluation Unit (SVEU) 213
 single nucleotide polymorphisms (SNP) 56, 131, 213
 Sjögren's syndrome 54, 120
 skin diseases 1, 50, 55, 97, 155, 191

- Small Business Biodefense Program 59
 Small Business Innovation Research (SBIR) 37, 204, 213, 228
 Small Business Technology Transfer (STTR) 37, 204, 213
 small grant 203
 smallpox 10, 21, 28, 30, 35, 57-60, 63-65, 72, 77-78, 147, 150
 specialized center 202
 St. Louis encephalitis virus (SLEV) 213
 Staphylococcus 46, 48, 58, 78, 91-92, 158, 210
 STD Clinical Trials Unit 74, 124
 STD Cooperative Research Centers 124
 STD Prevention Primate Unit 125
 Strategic Plan for Addressing Health Disparities 10
 strategic planning 8-10, 12
 Strategies for Management of Anti-Retroviral Therapies (SMART) 43-44, 213
Streptococcus agalactiae 98
Streptococcus pneumoniae 46, 92, 98
 structured intermittent therapy 44-45
 Summer Policy Retreat (SPR) 8, 213
 Summit on Development of Infectious Disease Therapeutics 74
 syphilis 74, 114, 121-122, 124-125, 144
 systemic lupus erythematosus (SLE) 54-55, 94, 96, 112, 120, 213
- T**
- T cell 26, 32, 34, 39, 41, 44, 45, 67, 68, 82, 94, 95, 96, 107, 136, 140, 147, 148, 155, 243
 technologies i, v, 2, 5, 16-17, 24, 26, 30, 32, 36, 59, 66-67, 75, 90-92, 113, 135, 140, 144, 146-147, 156, 159, 192-194, 198, 229, 230
 Technology Evaluation Advisory Committee (TEAC) 192, 213
 technology transfer vi, 5, 37, 135, 154, 156, 163, 192-193, 204, 212-213
 Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 13, 44, 71, 115, 119, 190, 207
 tetramer core facility 155-156
 Tetramer Facility 136, 148
 The Institute for Genomic Research (TIGR) 92-93, 134, 159, 213
 therapeutics ii, 2, 12, 13, 16, 21, 22, 23, 27, 43, 45, 48, 57, 59, 62, 64, 69-71, 73-76, 80-81, 83, 88, 92-93, 109, 113, 135, 154, 158, 196, 199, 227
- Therapeutics Research on AIDS-Associated Opportunistic Infections and Malignancies Program 16, 70-71
 thyroiditis 120
 topical microbicides 11, 16, 43, 74, 101, 114-115, 121-127
 Topical Microbicides Program 114, 121, 124
Toxoplasma gondii 58, 91, 98
 transmissible spongiform encephalopathy (TSE) 75-76, 87-89, 213
 transplantation iii, v, vi, 2, 10, 17-19, 36, 51, 54-55, 74-75, 94-96, 106-108, 111, 117, 121, 129-132, 135, 139, 146, 155, 156, 161,-163, 173-174, 181, 199, 206-207, 227-228
 treatment-related research 74
 trimethoprim-sulfamethoxazole (TMP-SMX) 47, 213
 tropical diseases 27, 99-100, 148, 160, 190
 Tropical Disease Research Units 100
 Tropical Medicine Research Center (TMRC) 213
 trypanosomiasis 98
 tuberculosis (TB) 6, 22-24, 47-48, 70-73, 75, 79, 81, 84, 91-92, 94, 113, 122, 133-139, 144, 147, 156, 161, 169, 210, 213
 Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) 71, 134, 213
 Tuberculosis Prevention Research Center 100
 Tuberculosis Research Unit (TBRU) 23, 133, 135, 213
 tularemia 10, 78
 typhoid fever 98
- U**
- U.S. Agency for International Development (USAID) 109-110, 213
 U.S. Army Medical Research and Materiel Command (USAMRMC) 42, 141, 143, 213
 U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) 33, 63-64, 82, 193, 213
 U.S.-Japan Cooperative Medical Science Program (USJCMSP) 102, 213
- V**
- Vaccine Action Program (VAP) 214
 Vaccine and Treatment Evaluation Unit (VTEU) 59, 148, 214
 vaccine candidates ii, 15-16, 30-34, 41, 59, 68, 87, 109, 113, 134, 137-138, 140, 144, 147, 149-150, 156, 162
 Vaccine Development Facility (VDF) 214

Vaccine Pilot Plant (VPP) 31, 150, 214
 vaccine research and development ii, v, 14, 22, 41-42, 139, 142, 148
 vaccinia 35, 42, 57-59, 63, 65, 72, 141, 150, 157, 161, 210
 vaginitis 98
 vancomycin-resistant enterococci (VRE) 46, 214
 varicella-zoster 76
 vasculitis 25
Vibrio cholerae 47, 91
 viral hemorrhagic fevers 33, 78, 157
 virion 69
 viruses iii, 17, 20, 25, 27-28, 30, 32, 40, 59, 64, 66, 72, 78-79, 81-82, 84, 86-87, 146, 148-149, 157-158, 193, 195, 198
 VRC. *See* Dale and Betty Bumpers Vaccine Research Center

W

Walter Reed Army Institute of Research 110, 152, 167, 171
 Warren Grant Magnuson Clinical Center 3, 25, 76
 Web sites iv, 6, 9-11, 13-15, 17, 19, 22-23, 25, 26, 29, 36-38, 44, 48, 53-55, 57, 67-68, 71, 73, 77-78, 83-84, 87, 92-94, 96-97, 103-104, 108, 111-113, 116-117, 120-121, 124, 131, 133-136, 147-148, 154-162, 166, 168, 171, 173, 176, 178, 180, 230

West Nile virus (WNV) 214
 Winter Program Review (WPR) 8, 214
Wolbachia 98
 Women and Infants Transmission Study (WITS) 11, 115, 119, 154, 214
 women's health v, 111, 118
 Women's Interagency HIV Study (WIHS) 11, 115, 119, 154, 214
 World Health Organization (WHO) iv, 6-7, 11, 23, 25, 28, 40, 43-44, 47, 58, 63-64, 73, 84-85, 95, 102, 105, 111-112, 114, 115, 117, 119-120, 125, 127, 129, 131, 133, 135, 151-154, 157, 160-161, 180, 190, 194, 201-202, 204, 210, 214
 World Reference Center for Arboviruses 83, 158

X

xenotransplantation 131

Y

yellow fever virus (YFV) 214
Yersinia pestis 58, 62, 78, 91

Z

zidovudine (AZT) 43, 161, 206